Image

Global Mucormycosis Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Sep 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Pharmaceutical
  • Upcoming Report
  • Sep 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Mucormycosis Market, By Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, Others), Fungi Type (Dermatophytes, Yeasts, Molds, Others), Route of Administration (Oral, Topical, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others) – Industry Trends and Forecast to 2029.

Mucormycosis Market

Mucormycosis Market Analysis and Size

The global mucormycosis market is expected to witness significant growth during the forecast period. There are certain risk factors that are associated with mucormycosis infection such as cancer, uncontrollable diabetes, organ transplant, and many more. About 1.5 million different species of fungi are present on the earth, but only about 300 are responsible for causing diseases and infections in humans. Rise in the well-defined reimbursement policies from public and private health insurance is the vital factor escalating the market growth. Sudden outbreak of the COVID-19 pandemic imposed stringent lockdown regulations globally, causing interruptions in import and export activities of global mucormycosis market.

Data Bridge Market Research analyses a growth rate in the global mucormycosis market in the forecast period 2022-2029. The expected CAGR of global mucormycosis market is tend to be around 4% in the mentioned forecast period. The market was valued at USD 500 million in 2021, and it would grow upto USD 684.28 million by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Mucormycosis is also known as zygomycosis. It is a rare type of fungal infection caused by numerous related molds called mucormycetes which resuts in the destruction of structures in the face. The symptoms of mucormycosis focus on the degree of tissue involvement; common ones include pain, fever, sinus pain and organ cellulitis. This disease prevalence is rising and important diagnostic procedures and treatments will boost the growth of the market.

Mucormycosis Market Scope and Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, Others), Fungi Type (Dermatophytes, Yeasts, Molds, Others), Route of Administration (Oral, Topical, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Market Players Covered

F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Sun Pharmaceutical Industries Ltd. (India), Merck & Co., Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Lilly (U.S.), Amgen Inc. (U.S.), Zydus Group (India), Lannett (U.S.), Wockhardt (India)

Market Opportunities

  • Increasing Demand for Retail Pharmacies
  • Higher Agreements by Organizations

Global Mucormycosis Market Dynamics

Drivers

  • Increased Government Initiatives

Indian government has provided license to many market players, to manufacture anti-fungal drug such as Amphotericin – B for the treatment of Mucormycosis. For instance, on May 22, 2021, Indian government provided license to five manufacturers namely Natco Pharmaceuticals, Gufic Biosciences, Alembic Pharmaceuticals, Emcure Pharmaceuticals, and Lyca Pharmaceuticals. These companies will start manufacturing 111,000 vials of Amphotericin – B every month from July 2021.Thus, it acts as a major driver in the market growth.

  • Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the global flavimonas oryzihabitans infection market. To encourage researchers and pharmaceutical companies to develop novel medicines, the government is funding research and development (R&D) initiatives.

Opportunities

  • Higher Agreements by Organizations

The growing agreements by the major market players for the manufacture of anti-fungal drug in the treatment of mucormycosis is anticipated to boost the growth of the market during the forecast period. For instance, on May 26, 2021, Cadila Healthcare Limited and TLC Pharma Labs agreed to manufacture anti-fungal drug ‘Liposomal Amphotericin B’ for treating patients having mucormycosis or black fungus in India. All these factors are also contributing in the growth of the market.  

  • Increasing Demand for Retail Pharmacies

The rise in the number of drugs used for global mucormycosis market delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.

Restraints/Challenges

  • Lack of skilled professionals

The lack of qualified personnel who are unable to perform these treatments could curb the growth of the global mucormycosis market over a forecast period.

  • Unavailability of Appropriate Treatments

To treat conditions which are rare, many a times all treatments are not available, especially in the under-developed countries. The severe patients needs to be treated with the advanced techniques but at times, these are not available in the hospitals and clinics. Thus, it hampers the market growth.

This global mucormycosis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global mucormycosis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Mucormycosis Market

Even though in the COVID-19 pandemic, the shift was on eradicating the infection and vaccine production but soon after, the mucormycosis was hit and the link between the two was established. Currently, mucormycosis infection cases are increasing among the people due to the occurrence of ideal environment in the COVID-19 patients, low oxygen, acidic medium (diabetic ketoacidosis and others), high iron levels, high glucose, and suppressed immune system along with other comorbidities. Government authorities are spreading more and more awareness for the early detection and management of mucormycosis in the COVID-19 patients.

Global Mucormycosis Market Scope

The global mucormycosis market is segmented on the basis of drug class, fungi type, route of administration, end-user, distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

  • Azoles
  • Echinocandins
  • Polyenes
  • Allylamines
  • Others 

Fungi Type

  • Dermatophytes
  • Yeasts
  • Molds
  • Others

Route of Administration

  • Oral
  • Topical
  • Others

End-Users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacies
  • Others

Mucormycosis Market Regional Analysis/Insights

The global mucormycosis market is analysed and market size insights and trends are provided by drug class, fungi type, route of administration, end-user, distribution channel as referenced above.

The major countries covered in the global mucormycosis market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is dominating the market due to global leaders in research and development activities and established healthcare infrastructure.

Asia-Pacific is considered to have the most lucrative period due to the developing healthcare facilities, large number of generic manufacturer and rise in government initiatives.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Mucormycosis Market Share Analysis

The global mucormycosis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global mucormycosis market.

Key players operating in the global mucormycosis market include:

  • F. Hoffmann-La Roche Ltd. (Switzerland)

  • Mylan N.V. (U.S.)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Sanofi (France)
  • Pfizer Inc. (U.S.)
  • GSK plc (U.K.)
  • Novartis AG (Switzerland)
  • AstraZeneca (U.K.)
  • Johnson & Johnson Private Limited (U.S.)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Merck & Co., Inc. (U.S.)
  • Bristol-Myers Squibb Company (U.S.)
  • Lilly (U.S.)
  • Amgen Inc. (U.S.)
  • Zydus Group (India)
  • Lannett (U.S.)
  • Wockhardt (India)


SKU-
Why Choose Us


Frequently Asked Questions

The future market growth of the Mucormycosis Market is expected USD 684.28 million by 2029.
The global mucormycosis market is projected to grow at a CAGR of 4% during the forecast period of 2022-2029.
The major players operating in the Mucormycosis Market are F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Sun Pharmaceutical Industries Ltd. (India), Merck & Co., Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Lilly (U.S.), Amgen Inc. (U.S.), Zydus Group (India), Lannett (U.S.), Wockhardt (India).
The major countries covered in the Mucormycosis Market are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.